S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$17.60
+0.28 (+1.62%)
(As of 02/23/2024 ET)
Today's Range
$17.05
$17.70
50-Day Range
$13.69
$17.60
52-Week Range
$13.62
$21.95
Volume
682,493 shs
Average Volume
529,669 shs
Market Capitalization
$6.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.59

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
11.3% Upside
$19.59 Price Target
Short Interest
Bearish
5.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Bausch + Lomb in the last 14 days
Based on 40 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
34.43%
From $0.61 to $0.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

461st out of 939 stocks

Ophthalmic Goods Industry

5th out of 7 stocks


BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Bausch + Lomb (NYSE:BLCO) PT Raised to $23.00
BHC Feb 2024 10.000 put
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Bausch + Lomb price target raised by $2 at Wells Fargo, here's why
Q4 2023 Bausch + Lomb Corp Earnings Call
Bausch + Lomb (NYSE:BLCO) Shares Gap Up After Strong Earnings
Needham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)
Bausch + Lomb gains after earnings beat
Emergent BioSolutions Appoints Joseph Papa As President And CEO
Bausch + Lomb Q4 Adj. Net Income Rises
Bausch + Lomb Q4 2023 Earnings Preview
Bausch & Lomb Earnings Preview
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/24/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Fax
N/A
Employees
12,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.59
High Stock Price Target
$25.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+11.3%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$6 million
Pretax Margin
-2.80%

Debt

Sales & Book Value

Annual Sales
$4.15 billion
Cash Flow
$2.31 per share
Book Value
$20.29 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.18 billion
Optionable
Optionable
Beta
0.24
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 54)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer














BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price target for 2024?

11 equities research analysts have issued twelve-month price objectives for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they expect the company's share price to reach $19.59 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2024?

Bausch + Lomb's stock was trading at $17.06 at the beginning of the year. Since then, BLCO shares have increased by 3.2% and is now trading at $17.60.
View the best growth stocks for 2024 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,280,000 shares, an increase of 16.3% from the January 15th total of 1,960,000 shares. Based on an average trading volume of 540,400 shares, the days-to-cover ratio is presently 4.2 days. Currently, 5.9% of the company's stock are short sold.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BLCO earnings forecast
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, February, 21st. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.07. The business earned $1.17 billion during the quarter, compared to analysts' expectations of $1.11 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive trailing twelve-month return on equity of 3.70%. The company's revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 EPS.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion.

When did Bausch + Lomb IPO?

(BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a variety of institutional and retail investors. Top institutional investors include FIL Ltd (2.31%), River Road Asset Management LLC (0.55%), Freshford Capital Management LLC (0.50%), Whitebox Advisors LLC (0.27%), Victory Capital Management Inc. (0.16%) and Gabelli Funds LLC (0.09%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 2/24/2024 by MarketBeat.com Staff